Trevena rockets up as post-'tummy tuck' pain drug clears Phase II

Trevena's ($TRVN) treatment for pain following abdominoplasty met its goals in a Phase IIb study, clearing the way for late-stage development and sending the company's share price soaring. The intravenous drug, TRV130, is a mu opioid receptor modulator designed to relieve pain following abdominoplasty, or tummy-tuck surgery. In a Phase IIb study involving 200 patients, the drug easily beat out placebo in reducing patient-reported pain and measured up to standard morphine on the same scale. More importantly, TRV130 notched significantly lower rates of vomiting, nausea and breathing problems compared with morphine, stoking hope that Trevena can duplicate the results in Phase III trials slated for next year and eventually hit the market with a disruptive pain treatment. The news sent Trevena's shares up roughly 45% on Tuesday. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.